Needham analyst Joseph Stringer has maintained their bullish stance on VIR stock, giving a Buy rating yesterday.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Stringer has given his Buy rating due to a combination of factors related to Vir Biotechnology’s promising developments in their Hepatitis Delta Virus (HDV) and oncology programs. The company’s focus on advancing its Ph3 HDV program, with significant data expected from three registrational trials by the first quarter of 2027, positions it well in a market estimated to be worth $1.5-2 billion, potentially more with increased diagnosis rates.
Additionally, Vir’s early-stage T-cell engager oncology programs, particularly the expansion of VIR-5500 in its Phase 1 trial, demonstrate a commitment to innovation and growth in the oncology sector. These strategic advancements, coupled with a robust cash balance of $811 million as of the third quarter of 2025, provide a solid foundation for future success and justify the Buy rating.